Addressing Obesity in America: Economics & Impact on Diverse Patient Communities

10.22.13 | By

The Partnership to Fight Chronic Disease
Addressing Obesity in America: Economics & Impact on Diverse Patient Communities
John J. Castellani, President & CEO, Pharmaceutical Research and Manufacturers of America
Los Angeles, CA
October 22, 2013

Thank you, Ken, for that kind introduction.

Greater collaboration is key to improving patient outcomes

10.21.13 | By

More than 30 million Americans suffer from rare diseases – conditions that are classified as such because they affect fewer than 200,000 people in the United States. Fortunately, there are more than 450 new medications in the pipeline to treat these conditions, and one-third of all new drug approvals over the last five years have been for medicines specific to rare diseases.

An Event Not to Be Missed

10.20.13 | By

Earlier this month, Bill Chin announced on this blog that PhRMA will be hosting a forum along with the Alzheimer’s Association and the Alzheimer’s Drug Discovery Foundation on Wednesday, October 23rd.

Bringing Patients Hope by Looking Ahead

10.18.13 | By

Tuesday began Medicare Part D Open Enrollment. With the program still going strong 10 years after it was enacted, Part D represents a significant milestone for patients.

Rare Disease Community Brings Knowledge, Passion and Ideas to #RarePOV Tweetchat

10.18.13 | By

The cultural anthropologist Margaret Mead once said, “Never doubt that a small group of thoughtful, committed citizens can change the world. Indeed, it is the only thing that ever has.”

Negotiating the TPP

10.17.13 | By

As the 12 countries negotiating the Trans-Pacific Partnership (TPP) approach the finish line after years of hard work on an ambitious agreement, there remains quite a bit of work left to be done. Now that all the low hanging fruit has been picked, the most difficult issues remain to be finalized. Not surprisingly, intellectual property (IP) is one of those issues 

Medicare Part D Open Enrollment

10.15.13 | By

Across the nation, millions of seniors and disabled Americans have access to innovative medicines through the Medicare prescription drug program (Part D). This year, we’re celebrating the 10-year anniversary of the program’s enactment, as well as taking note of the important feedback provided by those individuals who rely on it.

PhRMA Responds to New York TImes

Washington, D.C. (October 14, 2013) — Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John J. Castellani issued the following statement today:

Connecting Patients, Families, and Advocates

10.11.13 | By

Every day, our industry strives to connect patients, families and advocates from across the globe who share our common goals of preventing diseases, improving health and saving lives. Those strong voices of innovators and stakeholders working tirelessly to address pressing medical challenges, and many medical breakthroughs wouldn’t be possible today or in the future without them.

Greater Integration of Patient Input in Regulatory Decision-Making

10.10.13 | By

In the last 20 years, the Prescription Drug User Fee Act (PDUFA) has resulted in timelier patient access to more than 1,500 new drugs and biologics, decreasing review times for these treatments by more than 60 percent.

Pages

Subscribe to RSS - Opinion